We've just witnessed the fall of an ASX dividend aristocrat

Ramsay Health Care Limited (ASX: RHC) is now out of the running to be an ASX dividend aristocrat, at least until 2046. Here's why.

Over in the US, the term 'dividend aristocrat' is one that every investor knows.

It refers to a dividend-paying share that has increased said dividend non-stop for at least 25 years in a row.

Here in Australia, the term is less well known. Why? Because (as hard as it is to believe here in the land of franking credits) we simply don't have any.

And dividend kings – the stocks with a 50-year history of dividend raises? Nothing more than a regal legend on the ASX boards.

However, we do have some ASX shares that are getting close to true 'dividend aristocrat' status.

Take Washington H. Soul Pattinson and Co Ltd (ASX: SOL). Soul Patts has just increased its dividend for the 20th year in a row. 5 more and it will be crowned the ASX's first dividend aristocrat.

Unfortunately, this week, we lost another contender.

Ramsay Health Care Limited (ASX: RHC) had a dividend history to rival that of Soul Patts – delivering a dividend increase annually since 2000.

Until Monday.

a woman

ASX dividend aristocrat no more

Tragically, Ramsay will be starting from zero in 2021 after it announced its dividends will be suspended for the remainder of 2020.

The company has already paid an interim dividend in March. But if it doesn't pay a final dividend in 2020 (like it's told us it won't) the 20-year streak will come to an end.

Now, Ramsay must have broken its streak because it absolutely had to. We can gather from the ASX release (in which a capital raising was also announced) that its current cash flows have been so severely impacted by the coronavirus that there simply isn't the money there to fund dividend payments for ordinary shares.

But still, this is a sad week for Ramsay Health Care and its shareholders. The list of potential ASX dividend aristocrats grows thin indeed. After Ramsay, I'm watching Brickworks Limited (ASX: BKW) in this space. It's not far behind Soul Patts for dividend longevity. But who knows, maybe in 2046 Ramsay Health Care might finally wear that coveted crown.

Foolish takeaway

Even though I'm bitterly disappointed about this news from Ramsay, I'm still bullish on the long-term future of this company. It has a large network of impeccably-run private hospitals, both in Australia and across several other countries.

Healthcare is an 'evergreen' industry that will only benefit from the ageing population demographics across advanced economies well into the future.

Motley Fool contributor Sebastian Bowen owns shares of Ramsay Health Care Limited and Washington H. Soul Pattinson and Company Limited. The Motley Fool Australia owns shares of and has recommended Brickworks and Washington H. Soul Pattinson and Company Limited. The Motley Fool Australia has recommended Ramsay Health Care Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Doctor sees virtual images of the patient's x-rays on a blue background.
Healthcare Shares

Could this ASX biotech really jump more than 80% in value?

This company's new technology has one broker impressed.

Read more »

Teamwork, planning and meeting with doctors and laptop for medical, review and healthcare. Medicine, technology and internet with group of people for collaboration, diversity and support in hospital
Healthcare Shares

CSL vs Pro Medicus: Which ASX healthcare share is better?

Both CSL and Pro Medicus have faced recent challenges but have enviable long-term track records. Here's which one I'd buy…

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

This ASX biotech could rise almost 50%, Morgans says

Turning science into contracts could unlock value for this company.

Read more »

Doctor with stethoscope using a tablet in a hospital.
Healthcare Shares

Telix Pharmaceuticals wins FDA Fast Track for BiPASS prostate cancer imaging

Telix Pharmaceuticals shares are in the spotlight after the FDA granted Fast Track for its BiPASS pre-biopsy prostate cancer imaging…

Read more »

Three scientists looking at a laptop in a lab.
Healthcare Shares

What would it take for CSL shares to return to $250?

The shares have already recovered strongly, so I wanted to see whether $250 is realistic.

Read more »

Doctor with stethoscope typing on her computer.
Healthcare Shares

Is the ResMed share price a cheap buy?

I look at what the next few years of earnings growth could mean for today’s valuation.

Read more »

Medical workers examine an x-ray or scan in a hospital laboratory.
Healthcare Shares

Expert names 'undervalued' ASX 200 healthcare stock to buy today

A top fundie expects more outperformance from this resurgent ASX healthcare share.

Read more »

A gavel is placed on a stand on a desk with a legal representative wearing a suit in the background.
Healthcare Shares

Cochlear shares fall as investors face another setback

Cochlear shares are back in the red.

Read more »